{"id":83214,"date":"2026-07-29T00:05:31","date_gmt":"2026-07-29T00:05:31","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/cancervax-named-a-top-preclinical-biotech-company-of-2026-by-life-sciences-review\/"},"modified":"2026-07-29T00:05:31","modified_gmt":"2026-07-29T00:05:31","slug":"cancervax-named-a-top-preclinical-biotech-company-of-2026-by-life-sciences-review","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/cancervax-named-a-top-preclinical-biotech-company-of-2026-by-life-sciences-review\/","title":{"rendered":"CancerVax Named a Top Preclinical Biotech Company of 2026 by Life Sciences Review"},"content":{"rendered":"
\n

Independent industry recognition highlights the Company\u2019s revolutionary immunotherapy platform and growing momentum in precision cancer treatment<\/em><\/p>\n

Lehi, Utah, July 28, 2026 (GLOBE NEWSWIRE) — CancerVax, Inc.,<\/i> the developer of a breakthrough universal cancer treatment platform that \u201ctricks\u201d the body\u2019s immune system into fighting cancer, today announced it has been recognized by Life Sciences Review<\/i><\/b> as one of its Top Preclinical Biotech Companies of 2026<\/b>.<\/p>\n

As part of the recognition, Life Sciences Review<\/i> featured CancerVax in its annual showcase highlighting innovative biotechnology companies advancing the future of medicine. The publication also published a second in-depth editorial examining CancerVax\u2019s scientific approach and the potential impact of its novel immunotherapy platform. \u00a0<\/p>\n

\u201cWe are honored that Life Sciences Review<\/i> has recognized the potential of our revolutionary approach.\u201d said Byron Elton, Chief Executive Officer of CancerVax. \u201cThis recognition reflects the tremendous work of our scientific team and advisors who continue to push the boundaries of what may be possible in cancer immunotherapy,\u201d<\/p>\n

Unlike many existing immunotherapies that try to teach the immune system new immunities against cancer, CancerVax is developing a novel platform designed to \u201ctrick\u201d the immune system into attacking cancer. It does that by disguising cancer as common diseases and leveraging pre-existing antiviral immunities in most people. The Company\u2019s therapy is intended to selectively activate within cancer cells, causing those cells to display viral proteins that the immune system has previously learned to recognize through natural infections, vaccination, or exposure.<\/p>\n

Mr. Elton continued, \u201cBy making cancer cells look like well-immunized common diseases, such as measles or chickenpox, we believe the body’s natural immune system can kill cancer with precision and strength.\u201d<\/p>\n

Recent milestones announced by the Company include:<\/p>\n